Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
Brnardic, E.J., Garbaccio, R.M., Fraley, M.E., Tasber, E.S., Steen, J.T., Arrington, K.L., Dudkin, V.Y., Hartman, G.D., Stirdivant, S.M., Drakas, B.A., Rickert, K., Walsh, E.S., Hamilton, K., Buser, C.A., Hardwick, J., Tao, W., Beck, S.C., Mao, X., Lobell, R.B., Sepp-Lorenzino, L., Yan, Y., Ikuta, M., Munshi, S.K., Kuo, L.C., Kreatsoulas, C.(2007) Bioorg Med Chem Lett 17: 5989-5994
- PubMed: 17804227 
- DOI: 10.1016/j.bmcl.2007.07.051
- Primary Citation of Related Structures:  
2QHN, 2QHM - PubMed Abstract: 
The development of 2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-ones as inhibitors of Chk1 kinase is described. Introduction of a fused ring at the C7/C8 positions of the pyrazoloquinolinone provided an increase in potency while guidance from overlapping inh ...